OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. With a specific focus on tumor microenvironment, OREGA’s Target Discovery Program aims at discovering and validating novel clinically-relevant cancer targets.
The company was set up in 2010 by Nathalie Bonnefoy, PhD and Armand Bensussan, PhD, both at INSERM, Jean-François Eliaou, MD, Montpellier University and Gilles Alberici, PhD.
OREGA Biotech’s business strategy is to bring its R&D programs up to proof of concept, IND or early clinical stages and then to license them out to larger biotech or pharmaceutical companies. The company is building on a strong IP strategy, high level scientific publications and relies on a strong academic and industrial network. The company is managed by Gilles Alberici, PhD, CEO and Jeremy Bastid, PhD, COO. OREGA Biotech is funded by initiative Octalfa, SHAM Innovation Santé, Rhône-Alpes Création and INSERM-Transfert Initiative.